BP11133 PLGA 65:35, Carboxyl-Terminated, IV: 0.35–0.45 dl/g, Mw: 38–53 kDa

PLGA 65:35, Carboxyl-Terminated, IV: 0.35–0.45 dl/g, Mw: 38–53 kDa Description

PLGA 65:35, Carboxyl-Terminated, IV: 0.35–0.45 dl/g, Mw: 38–53 kDa is a copolymer of lactic and glycolic acids with a 65:35 ratio that maintains carboxyl end groups. The intrinsic viscosity range reflects its molecular design for uniform degradation behaviour. These specifications ensure the polymer can serve as a matrix for controlled drug release and resorbable implant materials while providing consistent performance due to its tailored hydrolysis rate.

PLGA 65:35, Carboxyl-Terminated, IV: 0.35–0.45 dl/g, Mw: 38–53 kDa Applications

Healthcare Applications
   - Used as a matrix in drug delivery systems to achieve sustained release by leveraging predictable hydrolytic degradation.
   - Applied as a resorbable scaffold in tissue engineering to support cell proliferation through its controlled erosion properties.

Industrial Applications
   - Employed in biodegradable packaging materials to address environmental disposal issues by utilising its controlled degradation kinetics.
   - Integrated in research settings as a model polymer for studying degradation mechanisms, facilitating the development of new biomaterials.

PLGA 65:35, Carboxyl-Terminated, IV: 0.35–0.45 dl/g, Mw: 38–53 kDa Packing

The product is packaged in moisture-resistant, sealed containers with an inner lining that minimises particulate contamination. Each container is further secured in a rigid, cushioned box to protect against physical damage during transit. Store in a cool, dry environment to maintain polymer integrity. Custom packaging options such as inert atmosphere sealing and temperature-control features are available upon request to optimise storage conditions.

Additional Information

PLGA polymers are widely studied in materials science due to their controlled degradation properties and biocompatibility. Researchers often analyse the interplay between molecular weight, copolymer ratio, and terminal group chemistry to fine-tune degradation rates for specific applications. These polymers serve as fundamental building blocks in the development of biomedical devices and resorbable implants.

Understanding the degradation mechanisms of PLGA in physiological environments provides insights into the design of drug delivery systems and tissue engineering scaffolds. The balance of hydrophilic and hydrophobic interactions within the polymer matrix governs its rate of hydrolysis, which is critical for ensuring consistent performance in both clinical and industrial contexts.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.